{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:27:08Z","timestamp":1786670828866,"version":"build-2736575974"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13559-1","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:54:11Z","timestamp":1780934051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Dolutegravir-based regimens on patient satisfaction and quality of life among people living with HIV: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Mustapha Muhammed","family":"Abubakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabel Ogechukwu","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Jeminiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifeanyi Kanayo","family":"Ifeorah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotanna","family":"Ezeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf","family":"Dauran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahabi","family":"Musa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silas Usen","family":"Joel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman Murtala","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amauche Pearl","family":"Ngige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Ezenri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulmuminu","family":"Isah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifunanya","family":"Ikhile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessing Onyinye","family":"Ukoha-Kalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"13559_CR1","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1097\/QAD.0000000000001870","volume":"32","author":"TG Harris","year":"2018","unstructured":"Harris TG, Rabkin M, El-Sadr WM. Achieving the fourth 90. AIDS. 2018;32:1563\u20139. https:\/\/doi.org\/10.1097\/QAD.0000000000001870.","journal-title":"AIDS"},{"key":"13559_CR2","unstructured":"Joint United Nations Programme on HIV\/AIDS. The PATH THAT ENDS AIDS 2023 UNAIDS GLOBAL AIDS UPDATE. 2023."},{"key":"13559_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","volume":"376","author":"PA Volberding","year":"2010","unstructured":"Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet. 2010;376:49\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(10)60676-9.","journal-title":"Lancet"},{"key":"13559_CR4","unstructured":"World Health Organization. UPDATE OF RECOMMENDATIONS ON FIRST-AND SECOND-LINE ANTIRETROVIRAL REGIMENS. 2019."},{"key":"13559_CR5","unstructured":"World Health Organization. Update on the transition to dolutegravir-based antiretroviral therapy: report of a WHO meeting, 29\u201330 March 2022. World Health Organization; 2022."},{"key":"13559_CR6","doi-asserted-by":"publisher","first-page":"101151","DOI":"10.1016\/j.ajogmf.2023.101151","volume":"5","author":"WN Kleinmann","year":"2023","unstructured":"Kleinmann WN, Pruszynski JE, Adhikari EH. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression. Am J Obstet Gynecol MFM. 2023;5:101151. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101151.","journal-title":"Am J Obstet Gynecol MFM"},{"key":"13559_CR7","doi-asserted-by":"publisher","unstructured":"Miller M, Liedtke MD, Rathbun RC, Lockhart SM. The role of dolutegravir in the management of HIV infections. Infect Drug Resist. 2015;19. https:\/\/doi.org\/10.2147\/IDR.S58706.","DOI":"10.2147\/IDR.S58706"},{"key":"13559_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/hiv.12888","volume":"21","author":"A Mocroft","year":"2020","unstructured":"Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, et al. Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-na\u00efve persons starting treatment. HIV Med. 2020;21:599\u2013606. https:\/\/doi.org\/10.1111\/hiv.12888.","journal-title":"HIV Med"},{"key":"13559_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1590\/0047-2085000000002","volume":"63","author":"P\u00dc Calvetti","year":"2014","unstructured":"Calvetti P\u00dc, Giovelli GRM, Gauer GJC, de Moraes JFD. Psychosocial factors associated with adherence to treatment and quality of life in people living with HIV\/AIDS in Brazil. J Bras Psiquiatr. 2014;63:8\u201315. https:\/\/doi.org\/10.1590\/0047-2085000000002.","journal-title":"J Bras Psiquiatr"},{"key":"13559_CR10","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1111\/hiv.13224","volume":"23","author":"R Harding","year":"2022","unstructured":"Harding R, Jones CI, Bremner S, Bristowe K, West B, Siegert RJ, et al. Positive Outcomes: Validity, reliability and responsiveness of a novel person-centred outcome measure for people with HIV. HIV Med. 2022;23:673\u201383. https:\/\/doi.org\/10.1111\/hiv.13224.","journal-title":"HIV Med"},{"key":"13559_CR11","doi-asserted-by":"publisher","unstructured":"Shirley ED, Sanders JO. Patient satisfaction: implications and predictors of success. J Bone Joint Surg Am. 2013;95:e69-1\u20134. https:\/\/doi.org\/10.2106\/JBJS.L.01048.","DOI":"10.2106\/JBJS.L.01048"},{"key":"13559_CR12","unstructured":"World Health Organization. WHOQOL User Manual Programme on Mental Health. 2012."},{"key":"13559_CR13","doi-asserted-by":"publisher","unstructured":"Graham G, Ware D, Plankey M. Patient-provider satisfaction and combination antiretroviral therapy adherence: an analysis of the association between health care satisfaction and adherence, as framed by the health belief model. Georgetown Med Rev. 2025;8. https:\/\/doi.org\/10.52504\/001c.127951.","DOI":"10.52504\/001c.127951"},{"key":"13559_CR14","doi-asserted-by":"publisher","first-page":"e0223723","DOI":"10.1371\/journal.pone.0223723","volume":"14","author":"BX Tran","year":"2019","unstructured":"Tran BX, Dang AK, Vu GT, Tran TT, Latkin CA, Ho CSH, et al. Patient satisfaction with HIV services in Vietnam: Status, service models and association with treatment outcome. PLoS ONE. 2019;14:e0223723. https:\/\/doi.org\/10.1371\/journal.pone.0223723.","journal-title":"PLoS ONE"},{"key":"13559_CR15","doi-asserted-by":"publisher","unstructured":"Tran DN, Manji I, Njuguna B, Kamano J, Laktabai J, Tonui E, et al. Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. BMJ Glob Health. 2020;5. https:\/\/doi.org\/10.1136\/bmjgh-2020-003116.","DOI":"10.1136\/bmjgh-2020-003116"},{"key":"13559_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12955-022-01985-z","volume":"20","author":"N Mengistu","year":"2022","unstructured":"Mengistu N, Hareru HE, Shumye S, Yimer S, Sisay D, Kaso AW, et al. Health related quality of life and its association with social support among people living with HIV\/AIDS receiving antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Health Qual Life Outcomes. 2022;20:77. https:\/\/doi.org\/10.1186\/s12955-022-01985-z.","journal-title":"Health Qual Life Outcomes"},{"key":"13559_CR17","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1186\/s12889-021-11321-7","volume":"21","author":"SSI Wardojo","year":"2021","unstructured":"Wardojo SSI, Huang Y-L, Chuang K-Y. Determinants of the quality of life amongst HIV clinic attendees in Malang, Indonesia. BMC Public Health. 2021;21:1272. https:\/\/doi.org\/10.1186\/s12889-021-11321-7.","journal-title":"BMC Public Health"},{"key":"13559_CR18","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s40249-017-0364-5","volume":"6","author":"J-F Xu","year":"2017","unstructured":"Xu J-F, Ming Z-Q, Zhang Y-Q, Wang P-C, Jing J, Cheng F. Family support, discrimination, and quality of life among ART-treated HIV-infected patients: a two-year study in China. Infect Dis Poverty. 2017;6:152. https:\/\/doi.org\/10.1186\/s40249-017-0364-5.","journal-title":"Infect Dis Poverty"},{"key":"13559_CR19","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1007\/s10461-021-03461-z","volume":"26","author":"C Hong","year":"2022","unstructured":"Hong C, Puttkammer N, Riabokon S, Germanovich M, Shost A, Parrish C, et al. Patient-Reported Treatment Satisfaction and Quality of Life Among People Living with HIV Following the Introduction of Dolutegravir-Based ART Regimens in Ukraine. AIDS Behav. 2022;26:1056\u201373. https:\/\/doi.org\/10.1007\/s10461-021-03461-z.","journal-title":"AIDS Behav"},{"key":"13559_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12879-024-09202-6","volume":"24","author":"N Hurbans","year":"2024","unstructured":"Hurbans N, Naidoo P. Efficacy, safety, and tolerability of dolutegravir-based ART regimen in Durban, South Africa: a cohort study. BMC Infect Dis. 2024;24:343. https:\/\/doi.org\/10.1186\/s12879-024-09202-6.","journal-title":"BMC Infect Dis"},{"key":"13559_CR21","doi-asserted-by":"publisher","unstructured":"Mehari EA, Muche EA, Gonete KA, Shiferaw KB. Treatment satisfaction and its associated factors of dolutegravir based regimen in a resource limited setting. Patient Prefer Adherence. 2021;15:1177\u201385. https:\/\/doi.org\/10.2147\/PPA.S308571.","DOI":"10.2147\/PPA.S308571"},{"key":"13559_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/hiv.12468","volume":"18","author":"C Hoffmann","year":"2017","unstructured":"Hoffmann C, Welz T, Sabranski M, Kolb M, Wolf E, Stellbrink H, et al. Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients. HIV Med. 2017;18:56\u201363. https:\/\/doi.org\/10.1111\/hiv.12468.","journal-title":"HIV Med"},{"key":"13559_CR23","doi-asserted-by":"publisher","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","volume":"48","author":"S Kanters","year":"2022","unstructured":"Kanters S, Renaud F, Rangaraj A, Zhang K, Limbrick-Oldfield E, Hughes M, et al. Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. EClinicalMedicine. 2022;48:101412. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101412.","journal-title":"EClinicalMedicine"},{"key":"13559_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1136\/sextrans-2020-054821","volume":"97","author":"A Allen Reeves","year":"2021","unstructured":"Allen Reeves A, Fuentes AV, Caballero J, Thomas JE, Mosley IIJF, Harrington C. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir\/rilpivirine: a meta-analysis. Sex Transm Infect. 2021;97:261\u20137. https:\/\/doi.org\/10.1136\/sextrans-2020-054821.","journal-title":"Sex Transm Infect"},{"key":"13559_CR25","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/hiv.13638","volume":"25","author":"S Sawry","year":"2024","unstructured":"Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk\u2010Heath M, Mthethwa S, et al. Assessment of weight gain in adult patients living with < scp>HIV receiving first\u2010line dolutegravir\u2010based or efavirenz\u2010based < scp>ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. HIV Med. 2024;25:826\u201339. https:\/\/doi.org\/10.1111\/hiv.13638.","journal-title":"HIV Med"},{"key":"13559_CR26","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"WDF Venter","year":"2020","unstructured":"Venter WDF, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020;7:e666\u201376. https:\/\/doi.org\/10.1016\/S2352-3018(20)30241-1.","journal-title":"Lancet HIV"},{"key":"13559_CR27","doi-asserted-by":"publisher","DOI":"10.37432\/jieph-d-25-00099","author":"MM Abubakar","year":"2025","unstructured":"Abubakar MM, Ifeorah IK, Bello AM, Isah A, Jeminiwa R, Joel SU, et al. Impact of Dolutegravir-based regimens on patient satisfaction and quality of life among people living with HIV: A systematic review and meta-analysis protocol. J Interventional Epidemiol Public Health. 2025. https:\/\/doi.org\/10.37432\/jieph-d-25-00099.","journal-title":"J Interventional Epidemiol Public Health"},{"key":"13559_CR28","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","volume":"310","author":"AG Florek","year":"2018","unstructured":"Florek AG, Wang CJ, Armstrong AW. Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review. Arch Dermatol Res. 2018;310:271\u2013319. https:\/\/doi.org\/10.1007\/s00403-018-1808-x.","journal-title":"Arch Dermatol Res"},{"key":"13559_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40520-020-01712-y","volume":"33","author":"D Pizzol","year":"2021","unstructured":"Pizzol D, Demurtas J, Celotto S, Maggi S, Smith L, Angiolelli G, et al. Urinary incontinence and quality of life: a systematic review and meta-analysis. Aging Clin Exp Res. 2021;33:25\u201335. https:\/\/doi.org\/10.1007\/s40520-020-01712-y.","journal-title":"Aging Clin Exp Res"},{"key":"13559_CR30","doi-asserted-by":"publisher","unstructured":"Pogorzelska K, Chlabicz S. Patient satisfaction with telemedicine during the COVID-19 pandemic\u2014a systematic review. Int J Environ Res Public Health. 2022;19. https:\/\/doi.org\/10.3390\/ijerph19106113.","DOI":"10.3390\/ijerph19106113"},{"key":"13559_CR31","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"13559_CR32","doi-asserted-by":"publisher","unstructured":"Gallardo-G\u00f3mez D, Richardson R, Dwan K. Standardized mean differences in meta\u2010analysis: a tutorial. Cochrane Evid Synth Methods. 2024;2. https:\/\/doi.org\/10.1002\/cesm.12047.","DOI":"10.1002\/cesm.12047"},{"key":"13559_CR33","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1080\/09540121.2021.1916873","volume":"34","author":"E Olliges","year":"2022","unstructured":"Olliges E, B\u00fchrlen B, Fischer F, Boesecke C, K\u00fcmmerle T, Schneider J, et al. Health-related quality-of-life in people living with HIV after switching to dual therapy with ritonavir-boosted darunavir + dolutegravir: a DUALIS sub-study. AIDS Care - Psychol Socio-Medical Aspects AIDS\/HIV. 2022;34:698\u2013707. https:\/\/doi.org\/10.1080\/09540121.2021.1916873.","journal-title":"AIDS Care - Psychol Socio-Medical Aspects AIDS\/HIV"},{"key":"13559_CR34","doi-asserted-by":"publisher","unstructured":"Costa J, de Pearson O, Acurcio SA, de Bonolo F, de Silveira P, Ceccato MR. M das GB. Health-related quality of life among HIV-infected patients initiating treatment in Brazil in the single-tablet regimen era. AIDS Care. 2019;31:572\u201381. https:\/\/doi.org\/10.1080\/09540121.2019.1576841.","DOI":"10.1080\/09540121.2019.1576841"},{"key":"13559_CR35","doi-asserted-by":"publisher","unstructured":"Ochanda PN, Lamorde M, Kintu K, Wang D, Chen T, Malaba T, et al. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy. AIDS Res Ther. 2022;19. https:\/\/doi.org\/10.1186\/s12981-022-00446-3.","DOI":"10.1186\/s12981-022-00446-3"},{"key":"13559_CR36","doi-asserted-by":"publisher","unstructured":"Gudala GR, Padayachee N, Vagiri RV. Beyond antiretroviral treatment: health-related quality of life of patients receiving antiretroviral treatment at a tertiary hospital in South Africa. Dialogues Health. 2025;6. https:\/\/doi.org\/10.1016\/j.dialog.2025.100207.","DOI":"10.1016\/j.dialog.2025.100207"},{"key":"13559_CR37","doi-asserted-by":"publisher","unstructured":"Sculier D, Wandeler G, Yerly S, Marinosci A, Stoeckle M, Bernasconi E, et al. Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL\u2019HIV trial. PLoS Med. 2020;17. https:\/\/doi.org\/10.1371\/journal.pmed.1003421.","DOI":"10.1371\/journal.pmed.1003421"},{"key":"13559_CR38","doi-asserted-by":"publisher","unstructured":"Marinosci A, Sculier D, Wandeler G, Yerly S, Stoeckle M, Bernasconi E, et al. Efficacy and safety of dolutegravir plus emtricitabine vs combined antiretroviral therapy for the maintenance of HIV suppression: results through week 144 of the SIMPL\u2019HIV trial. Open Forum Infect Dis. 2024;11. https:\/\/doi.org\/10.1093\/ofid\/ofae618.","DOI":"10.1093\/ofid\/ofae618"},{"key":"13559_CR39","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00228-018-2472-y","volume":"74","author":"JC Mendes","year":"2018","unstructured":"Mendes JC, Bonolo P, de F, Ceccato M, das GB, Costa J, de O, Reis AMM, dos Santos H, et al. Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy. Eur J Clin Pharmacol. 2018;74:1077\u201388. https:\/\/doi.org\/10.1007\/s00228-018-2472-y.","journal-title":"Eur J Clin Pharmacol"},{"key":"13559_CR40","doi-asserted-by":"publisher","unstructured":"Umar D, Waziri B, Ndagi U, Mohammed S, Usman N, Abubakar-Muhammad H. Impact of Tenofovir\/Lamivudine\/Dolutegravir (TLD) on the health-related quality of life and clinical outcomes of HIV\/AIDS patients at a tertiary health facility in Niger State. 2020. https:\/\/doi.org\/10.21203\/rs.3.rs-127277\/v1.","DOI":"10.21203\/rs.3.rs-127277\/v1"},{"key":"13559_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11606\/s1518-8787.2020054001920","volume":"54","author":"GS Pimentel","year":"2020","unstructured":"Pimentel GS, das Gra\u00e7as Braga Ceccato M, de Oliveira Costa J, Mendes JC, de F\u00e1tima Bonolo P, Silveira MR. Quality of life in individuals initiating antiretroviral therapy: a cohort study. Rev Saude Publica. 2020;54:1\u201314. https:\/\/doi.org\/10.11606\/s1518-8787.2020054001920.","journal-title":"Rev Saude Publica"},{"key":"13559_CR42","doi-asserted-by":"crossref","unstructured":"Poliseno M, Mazzitelli M, Narducci A, Ferrara SM, Resnati C, Gervasoni C, et al. Doravirine plus integrase strand transfer inhibitors as a 2-drug treatment-switch strategy in people living with HIV: the real-life dorini multicentric cohort study. 2023.","DOI":"10.1097\/QAI.0000000000003248"},{"key":"13559_CR43","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10461-024-04479-9","volume":"29","author":"P Kumar","year":"2025","unstructured":"Kumar P, Clarke AE, Jonsson-Oldenb\u00fcttel C, Deltoro MG, Di Giambenedetto S, Brites C, et al. Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir\/Lamivudine: 48-Week Results from the SALSA Study. AIDS Behav. 2025;29:235\u201345. https:\/\/doi.org\/10.1007\/s10461-024-04479-9.","journal-title":"AIDS Behav"},{"key":"13559_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.medmal.2018.11.012","volume":"49","author":"C Allavena","year":"2019","unstructured":"Allavena C, Volteau C, Andr\u00e9-Garnier E, Guimard T, Hall N, Khatchatourian L, et al. Switching from abacavir\/lamivudine plus nevirapine to abacavir\/lamivudine\/dolutegravir in virologically controlled HIV-infected adults (SWAD study). Med Mal Infect. 2019;49:505\u201310. https:\/\/doi.org\/10.1016\/j.medmal.2018.11.012.","journal-title":"Med Mal Infect"},{"key":"13559_CR45","doi-asserted-by":"publisher","unstructured":"Hidalgo-Tenorio C, Pasquau J, Vinuesa D, Ferra S, Terr\u00f3n A, Sanjoaqu\u00edn I, et al. DOLAVI real-life study of dolutegravir plus lamivudine in naive HIV-1 patients (48 Weeks). Viruses. 2022;14. https:\/\/doi.org\/10.3390\/v14030524.","DOI":"10.3390\/v14030524"},{"key":"13559_CR46","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3851\/IMP3166","volume":"22","author":"B Trottier","year":"2017","unstructured":"Trottier B, Lake JE, Logue K, Brinson C, Santiago L, Brennan C, et al. Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study. Antivir Ther. 2017;22:295\u2013305. https:\/\/doi.org\/10.3851\/IMP3166.","journal-title":"Antivir Ther"},{"key":"13559_CR47","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40121-024-01083-1","volume":"14","author":"B Rossetti","year":"2025","unstructured":"Rossetti B, Ferrara M, Taramasso L, Bai F, Lombardi F, Ciccarelli N, et al. Evolution of Self-reported Neuropsychiatric Symptoms After Switching from Dolutegravir\/Abacavir\/Lamivudine to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: Results from the Randomized DOBINeuro Trial. Infect Dis Ther. 2025;14:293\u2013304. https:\/\/doi.org\/10.1007\/s40121-024-01083-1.","journal-title":"Infect Dis Ther"},{"key":"13559_CR48","doi-asserted-by":"publisher","unstructured":"Pane MR, Yunihastuti E, Putranto R, Widhani A, Koesnoe S, Shatri H, et al. Quality-of-life changes six months after the programmatic switch from nevirapine to dolutegravir-based ART in stable PLWH: a prospective cohort study in Indonesia. Sci Rep. 2025;15. https:\/\/doi.org\/10.1038\/s41598-025-13931-2.","DOI":"10.1038\/s41598-025-13931-2"},{"key":"13559_CR49","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1080\/09540120412331290194","volume":"16","author":"Whoqol Hiv Group","year":"2004","unstructured":"Whoqol Hiv Group. WHOQOL-HIV for quality of life assessment among people living with HIV and AIDS: results from the field test. AIDS Care. 2004;16:882\u20139. https:\/\/doi.org\/10.1080\/09540120412331290194.","journal-title":"AIDS Care"},{"key":"13559_CR50","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2147\/prom.s239429","volume":"11","author":"T Melaku","year":"2020","unstructured":"Melaku T, Mamo G, Chelkeba L, Chanie T. Health-Related Quality of Life Among People Living with Human Immunodeficiency Virus on Highly Active Antiretroviral Therapy in Ethiopia: PROQOL-HIV Based Survey. Patient Relat Outcome Meas. 2020;11:73\u201386. https:\/\/doi.org\/10.2147\/prom.s239429.","journal-title":"Patient Relat Outcome Meas"},{"key":"13559_CR51","doi-asserted-by":"publisher","unstructured":"Duracinsky M, Herrmann S, Berzins B, Armstrong AR, Kohli R, Coeur S, Le, et al. The development of PROQOL-HIV: an international instrument to assess the health-related quality of life of persons living with HIV\/AIDS. J Acquir Immune Defic Syndr. 2012;59:498\u2013505. https:\/\/doi.org\/10.1097\/QAI.0b013e318245cafe.","DOI":"10.1097\/QAI.0b013e318245cafe"},{"key":"13559_CR52","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/09540120903207292","volume":"22","author":"WA Henderson","year":"2010","unstructured":"Henderson WA, Schlenk EA, Kim KH, Hadigan CM, Martino AC, Sereika SM, et al. Validation of the MOS-HIV as a measure of health-related quality of life in persons living with HIV and liver disease. AIDS Care - Psychol Socio-Medical Aspects AIDS\/HIV. 2010;22:483\u201390. https:\/\/doi.org\/10.1080\/09540120903207292.","journal-title":"AIDS Care - Psychol Socio-Medical Aspects AIDS\/HIV"},{"key":"13559_CR53","doi-asserted-by":"publisher","unstructured":"Tarekegn TB, Gebrie D, Kassaw AT, Dagne Taye A, Girmaw F, Ashagrie G. Evaluating health-related quality of life in Ethiopia: systematic review and meta-analysis of EQ-5D-based studies. Front Epidemiol. 2024;4. https:\/\/doi.org\/10.3389\/fepid.2024.1455822.","DOI":"10.3389\/fepid.2024.1455822"},{"key":"13559_CR54","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1007\/s10461-024-04496-8","volume":"28","author":"JR Valdelamar-Jim\u00e9nez","year":"2024","unstructured":"Valdelamar-Jim\u00e9nez JR, Narv\u00e1ez Betancur MB, Brites C, Lins-Kusterer L. Validation of the HIV\/AIDS-Targeted Quality of Life (HAT-QOL) for Evaluation of Health-related Quality of Life in People Living with HIV\/AIDS in Brazil. AIDS Behav. 2024;28:4188\u201398. https:\/\/doi.org\/10.1007\/s10461-024-04496-8.","journal-title":"AIDS Behav"},{"key":"13559_CR55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1023\/A:1013050904635","volume":"10","author":"A Woodcock","year":"2001","unstructured":"Woodcock A, Bradley C. Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ). Qual Life Res. 2001;10:517\u201331. https:\/\/doi.org\/10.1023\/A:1013050904635.","journal-title":"Qual Life Res"},{"key":"13559_CR56","doi-asserted-by":"publisher","unstructured":"Akbulut I, Varol ZS, \u00d6demi\u015f I, Ero\u011ful E, Atalay S, G\u00f6kengin AD. HIV treatment satisfaction: HIVTSQ-12 factor analysis and associated factors in T\u00fcrkiye. BMC Infect Dis. 2024;24. https:\/\/doi.org\/10.1186\/s12879-024-10251-0.","DOI":"10.1186\/s12879-024-10251-0"},{"key":"13559_CR57","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.vhri.2020.07.578","volume":"23","author":"ACS Liberato","year":"2020","unstructured":"Liberato ACS, S\u00e3o Jo\u00e3o TM, Jannuzzi FF, Landaas EJ, Wongchareon K, Rodrigues RCM. Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4): Ceiling and Floor Effects, Reliability, and Known-Group Validity in Brazilian Outpatients With Hypertension. Value Health Reg Issues. 2020;23:150\u20136. https:\/\/doi.org\/10.1016\/j.vhri.2020.07.578.","journal-title":"Value Health Reg Issues"},{"key":"13559_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12916-016-0640-4","volume":"14","author":"JV Lazarus","year":"2016","unstructured":"Lazarus JV, Safreed-Harmon K, Barton SE, Costagliola D, Dedes N, del Amo Valero J, et al. Beyond viral suppression of HIV \u2013 the new quality of life frontier. BMC Med. 2016;14:94. https:\/\/doi.org\/10.1186\/s12916-016-0640-4.","journal-title":"BMC Med"},{"key":"13559_CR59","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jmii.2023.01.015","volume":"56","author":"LY Chen","year":"2023","unstructured":"Chen LY, Sun HY, Chuang YC, Huang YS, Liu W, Da, Lin KY, et al. Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide. J Microbiol Immunol Infect. 2023;56:575\u201385. https:\/\/doi.org\/10.1016\/j.jmii.2023.01.015.","journal-title":"J Microbiol Immunol Infect"},{"key":"13559_CR60","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-025-01252-w","author":"A Antinori","year":"2025","unstructured":"Antinori A, Yokomaku Y, Elinav H, Pulluk\u00e7u H, de Wet J, Antela A, et al. Quality of Life and Treatment Satisfaction in People with HIV Switching to Bictegravir\/Emtricitabine\/Tenofovir Alafenamide: Pooled Analysis from Observational Cohort Studies. Infect Dis Ther. 2025. https:\/\/doi.org\/10.1007\/s40121-025-01252-w.","journal-title":"Infect Dis Ther"},{"key":"13559_CR61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/hiv.13593","volume":"25","author":"S Esser","year":"2024","unstructured":"Esser S, Brunetta J, Inciarte A, Levy I, D\u2019Arminio Monforte A, Lambert JS, et al. Twelve-month effectiveness and safety of bictegravir\/emtricitabine\/tenofovir alafenamide in people with < scp>HIV: Real\u2010world insights from < scp>BICSTaR cohorts. HIV Med. 2024;25:440\u201353. https:\/\/doi.org\/10.1111\/hiv.13593.","journal-title":"HIV Med"},{"key":"13559_CR62","doi-asserted-by":"publisher","unstructured":"Cruciani M, Parisi SG. Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: a systematic review and metaanalysis. PLoS ONE. 2019;14. https:\/\/doi.org\/10.1371\/journal.pone.0222229.","DOI":"10.1371\/journal.pone.0222229"},{"key":"13559_CR63","doi-asserted-by":"publisher","first-page":"e43558","DOI":"10.1097\/MD.0000000000043558","volume":"104","author":"A Doblado-Maldonado","year":"2025","unstructured":"Doblado-Maldonado A, Ooi AYR, Cheng CY, Sun W, Letang E, Moorhouse M, et al. Dolutegravir + lamivudine effectiveness and tolerability in real-world cohorts with HIV-1 across Asia and South America: A systematic literature review. Med (United States). 2025;104:e43558. https:\/\/doi.org\/10.1097\/MD.0000000000043558.","journal-title":"Med (United States)"},{"key":"13559_CR64","doi-asserted-by":"publisher","first-page":"25961","DOI":"10.1002\/jia2.25961\/full","volume":"2022","author":"ML Romo","year":"2022","unstructured":"Romo ML, Brazier E, Mahambou-Nsond\u00e9 D, De Waal R, Sekaggya-Wiltshire C, Chimbetete C, et al. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa. J Int AIDS Soc. 2022;2022:25961. https:\/\/doi.org\/10.1002\/jia2.25961\/full.","journal-title":"J Int AIDS Soc"},{"key":"13559_CR65","doi-asserted-by":"publisher","unstructured":"Mutagonda RF, Mlyuka HJ, Maganda BA, Kamuhabwa AAR. Adherence, effectiveness and safety of dolutegravir based antiretroviral regimens among HIV infected children and adolescents in Tanzania. J Int Assoc Provid AIDS Care. 2022;21. https:\/\/doi.org\/10.1177\/23259582221109613.","DOI":"10.1177\/23259582221109613"},{"key":"13559_CR66","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40265-013-0040-4","volume":"73","author":"H Gakhar","year":"2013","unstructured":"Gakhar H, Kamali A, Holodniy M. Health-related Quality of Life Assessment after Antiretroviral Therapy: A Review of the Literature. Drugs. 2013;73:651\u201372. https:\/\/doi.org\/10.1007\/s40265-013-0040-4.","journal-title":"Drugs"},{"key":"13559_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/HIV.S32321","volume":"4","author":"OO Oguntibeju","year":"2012","unstructured":"Oguntibeju OO. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV\/AIDS - Res Palliat Care. 2012;4:117\u201324. https:\/\/doi.org\/10.2147\/HIV.S32321.","journal-title":"HIV\/AIDS - Res Palliat Care"},{"key":"13559_CR68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/00042560-200203010-00004","volume":"29","author":"CR Fumaz","year":"2002","unstructured":"Fumaz CR, Tuldr\u00e0 A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, et al. Quality of Life, Emotional Status, and Adherence of HIV-1\u2013Infected Patients Treated With Efavirenz Versus Protease Inhibitor\u2013Containing Regimens. JAIDS J Acquir Immune Defic Syndr. 2002;29:244\u201353. https:\/\/doi.org\/10.1097\/00042560-200203010-00004.","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"13559_CR69","doi-asserted-by":"publisher","first-page":"26350","DOI":"10.1002\/jia2.26350\/full","volume":"27","author":"Z Wagner","year":"2024","unstructured":"Wagner Z, Wang Z, Stecher C, Karamagi Y, Odiit M, Haberer JE, et al. The association between adherence to antiretroviral therapy and viral suppression under dolutegravir-based regimens: an observational cohort study from Uganda. J Int AIDS Soc. 2024;27:26350. https:\/\/doi.org\/10.1002\/jia2.26350\/full.","journal-title":"J Int AIDS Soc"},{"key":"13559_CR70","doi-asserted-by":"publisher","unstructured":"Jemal M, Adugna A, Getinet M, Ashenef B, Baye G, Abebaw D, et al. Dyslipidemia and its associated factors among people living with HIV on dolutegravir-based antiretroviral therapy at Debre Markos Comprehensive Specialized Hospital, Northwest Ethiopia: a cross-sectional study. AIDS Res Treat. 2025;2025. https:\/\/doi.org\/10.1155\/arat\/6621097.","DOI":"10.1155\/arat\/6621097"},{"key":"13559_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.33393\/dti.2023.2529","volume":"17","author":"S Khemla","year":"2023","unstructured":"Khemla S, Meesing A, Sribenjalux W, Chetchotisakd P. Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir. Drug Target Insights. 2023;17:45\u201353. https:\/\/doi.org\/10.33393\/dti.2023.2529.","journal-title":"Drug Target Insights"},{"key":"13559_CR72","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","volume":"31","author":"JM Gatell","year":"2017","unstructured":"Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, et al. Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS. 2017;31:2503\u201314. https:\/\/doi.org\/10.1097\/QAD.0000000000001675.","journal-title":"AIDS"},{"key":"13559_CR73","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.4103\/jfmpc.jfmpc_411_18","volume":"8","author":"C Shriharsha","year":"2019","unstructured":"Shriharsha C, Rentala S. Quality of life among people living with HIV\/AIDS and its predictors: A cross-sectional study at ART center, Bagalkot, Karnataka. J Family Med Prim Care. 2019;8:1011. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_411_18.","journal-title":"J Family Med Prim Care"},{"key":"13559_CR74","doi-asserted-by":"publisher","unstructured":"Oladejo TS, Myezwa H, Ajidahun AT, Ibeneme S. Health-related quality of life and associated factors among people living with HIV\/AIDS in Lagos, Nigeria. Afr J Prim Health Care Fam Med. 2024;16. https:\/\/doi.org\/10.4102\/phcfm.v16i1.4519.","DOI":"10.4102\/phcfm.v16i1.4519"},{"key":"13559_CR75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1089\/apc.2012.0329","volume":"27","author":"AT Rodriguez-Penney","year":"2013","unstructured":"Rodriguez-Penney AT, Iudicello JE, Riggs PK, Doyle K, Ellis RJ, Letendre SL, et al. Co-morbidities in persons infected with HIV: Increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27:5\u201316. https:\/\/doi.org\/10.1089\/apc.2012.0329.","journal-title":"AIDS Patient Care STDS"},{"key":"13559_CR76","doi-asserted-by":"publisher","unstructured":"Owusu R, Kwarteng EB, Bawua SA, Otoo DD, Nonvignon J. Health-related quality of life of HIV patients with comorbidities of hypertension or diabetes in Ghana. Front Public Health 2024;12. https:\/\/doi.org\/10.3389\/fpubh.2024.1383743.","DOI":"10.3389\/fpubh.2024.1383743"},{"key":"13559_CR77","doi-asserted-by":"publisher","unstructured":"Ahmad DM, Muhammad HR, Aliyu S, Lucero-Prisno DE. Comparison of the quality of life of comorbid and non-comorbid people living with HIV\/AIDS in a Nigerian secondary healthcare facility. J Multimorbidity Comorbidity. 2024;14. https:\/\/doi.org\/10.1177\/26335565241293930.","DOI":"10.1177\/26335565241293930"},{"key":"13559_CR78","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(00)02854-3","volume":"356","author":"A Carr","year":"2000","unstructured":"Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356:1423\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(00)02854-3.","journal-title":"Lancet"},{"key":"13559_CR79","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1186\/s12879-025-11996-y","volume":"25","author":"MM Abubakar","year":"2025","unstructured":"Abubakar MM, Isah A, Jeminiwa R, Abioye I, Yunusa I, Abba-Aji M, et al. Prevalence of potentially inappropriate medications in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis. 2025;25:1571. https:\/\/doi.org\/10.1186\/s12879-025-11996-y.","journal-title":"BMC Infect Dis"},{"key":"13559_CR80","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.hivar.2014.07.004","volume":"14","author":"IA Syed","year":"2015","unstructured":"Syed IA, Sulaiman SAS, Hassali MA, Lee CKC. Adverse drug reactions and quality of life in HIV\/AIDS patients: Advocacy on valuation and role of pharmacovigilance in developing countries. HIV AIDS Rev. 2015;14:28\u201330. https:\/\/doi.org\/10.1016\/j.hivar.2014.07.004.","journal-title":"HIV AIDS Rev"},{"key":"13559_CR81","doi-asserted-by":"publisher","unstructured":"Ghiasvand H, Waye KM, Noroozi M, Harouni GG, Armoon B, Bayani A. Clinical determinants associated with quality of life for people who live with HIV\/AIDS: a meta-analysis. BMC Health Serv Res. 2019;19. https:\/\/doi.org\/10.1186\/s12913-019-4659-z.","DOI":"10.1186\/s12913-019-4659-z"},{"key":"13559_CR82","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jrsm.46","volume":"2","author":"K Thorlund","year":"2011","unstructured":"Thorlund K, Walter SD, Johnston BC, Furukawa TA, Guyatt GH. Pooling health-related quality of life outcomes in meta-analysis\u2014a tutorial and review of methods for enhancing interpretability. Res Synth Methods. 2011;2:188\u2013203. . https:\/\/doi.org\/10.1002\/jrsm.46","journal-title":"Res Synth Methods"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13559-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13559-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:38:54Z","timestamp":1786667934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13559-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":82,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13559"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13559-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethics review was required as the study involved analysis of published studies.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1487"}}